These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15568146)

  • 1. [Molecular biology of the heart atrium. New insights into the pathophysiology of atrial fibrillation as well as its clinical implications].
    Goette A; Lendeckel U; Klein HU
    Z Kardiol; 2004 Nov; 93(11):864-77. PubMed ID: 15568146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonchannel drug targets in atrial fibrillation.
    Goette A; Lendeckel U
    Pharmacol Ther; 2004 Apr; 102(1):17-36. PubMed ID: 15056496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Morphological remodeling in atrial fibrillation].
    Goette A; Lendeckel U
    Herz; 2006 Apr; 31(2):101-7; quiz 142-3. PubMed ID: 16738831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling).
    Goette A; Bukowska A; Lendeckel U
    Curr Opin Pharmacol; 2007 Apr; 7(2):219-24. PubMed ID: 17276728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of atrial fibrillation.
    Bajpai A; Savelieva I; Camm AJ
    Br Med Bull; 2008; 88(1):75-94. PubMed ID: 19059992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Class 1 antiarrhythmic agents for therapy of atrial fibrillation.
    Podrid PJ
    Herz; 1993 Feb; 18(1):9-19. PubMed ID: 8454255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model.
    Zhao Z; Chen Y; Li W; Wang X; Li J; Yang W; Cheng L; Liu T; Liu E; Li G
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):863-71. PubMed ID: 27118660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New directions in antiarrhythmic drug therapy for atrial fibrillation.
    Heijman J; Voigt N; Dobrev D
    Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of atrial remodeling and clinical relevance.
    Nattel S; Shiroshita-Takeshita A; Cardin S; Pelletier P
    Curr Opin Cardiol; 2005 Jan; 20(1):21-5. PubMed ID: 15596955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapy of atrial fibrillation: a pathophysiological perspective and review.
    Jacob S; Ali OA; Pidlaoan V; Badheka AO; Kerin NZ
    Am J Ther; 2011 May; 18(3):241-60. PubMed ID: 20861719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionation of electrograms and linking of activation during pharmacologic cardioversion of persistent atrial fibrillation in the goat.
    Shan Z; Van Der Voort PH; Blaauw Y; Duytschaever M; Allessie MA
    J Cardiovasc Electrophysiol; 2004 May; 15(5):572-80. PubMed ID: 15149428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anti-arrhythmic agents for the treatment of atrial fibrillation.
    Wettwer E; Christ T; Dobrev D; Ravens U
    Curr Opin Pharmacol; 2007 Apr; 7(2):214-8. PubMed ID: 17303472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrical remodeling in atrial fibrillation.
    Dobrev D
    Herz; 2006 Apr; 31(2):108-12; quiz 142-3. PubMed ID: 16738832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives and challenges of antioxidant therapy for atrial fibrillation.
    Gasparova I; Kubatka P; Opatrilova R; Caprnda M; Filipova S; Rodrigo L; Malan L; Mozos I; Rabajdova M; Nosal V; Kobyliak N; Valentova V; Petrovic D; Adamek M; Kruzliak P
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):1-14. PubMed ID: 27900409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atrial remodeling and anti-remodeling therapy in atrial fibrillation].
    Neumann T; Hölschermann H
    Dtsch Med Wochenschr; 2006 Apr; 131(16):884-7. PubMed ID: 16625482
    [No Abstract]   [Full Text] [Related]  

  • 17. Atrial remodeling and novel pharmacological strategies for antiarrhythmic therapy in atrial fibrillation.
    Jost N; Kohajda Z; Kristóf A; Kovács PP; Husti Z; Juhász V; Kiss L; Varró A; Virág L; Baczkó I
    Curr Med Chem; 2011; 18(24):3675-94. PubMed ID: 21774760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation.
    Burstein B; Nattel S
    J Am Coll Cardiol; 2008 Feb; 51(8):802-9. PubMed ID: 18294563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Restoration and maintenance of sinus rhythm in patients with atrial fibrillation. New pharmacological approaches].
    Runge S; Dietz R; Haverkamp W
    Dtsch Med Wochenschr; 2008 Dec; 133(49):2572-8. PubMed ID: 19039713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Upstream therapy for atrial fibrillation].
    Goette A; Hammwöhner M; Bukowska A
    Herzschrittmacherther Elektrophysiol; 2014 Mar; 25(1):33-40. PubMed ID: 24519662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.